Buy AOD-9604 – Peptide Partners

Product Overview & Specifications

AOD-9604 is a synthetic research peptide corresponding to the C-terminal fragment of human growth hormone. Peptide Partners supplies AOD-9604 for in-vitro testing, laboratory experimentation, and metabolic or preclinical research.

Research on AOD-9604 has examined lipid metabolism, adipocyte biology, lipolysis-related pathways, β3-adrenergic receptor expression, acetyl-CoA carboxylase activity, peptide degradation, and analytical detection in biological matrices. These studies are limited to laboratory, non-clinical, and animal models and do not establish human safety, efficacy, or clinical outcomes.

Product Specifications

The stated 99.93% purity is based on multi-vial testing. Researchers should review the applicable batch documentation and certificate of analysis before beginning any experiment.

Primary Research Studies & Findings

The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice and β3-AR Knock-Out Mice

Authors: Mark Heffernan, Roger J. Summers, Anne Thorburn, Esra Ogru, Robert Gianello, Woei-Jia Jiang, and Frank M. Ng

Publication: Endocrinology, 2001;142(12):5182–5189

DOI: 10.1210/endo.142.12.8522

Reference: View publication

This study examined AOD9604 and human growth hormone in obese mice, β3-adrenergic receptor knockout mice, and mouse and human cell systems. The researchers assessed β3-adrenergic receptor RNA expression, protein levels, receptor function, lipolytic sensitivity, and changes associated with lipid metabolism.

The study reported that AOD9604 increased β3-adrenergic receptor expression in relevant experimental systems. It also examined the peptide’s relationship with acetyl-CoA carboxylase activity in hepatocytes and adipocytes. In obese mice, chronic treatment was associated with changes in body weight and lipolytic sensitivity, while experiments in β3-adrenergic receptor knockout mice were used to investigate the role of that receptor pathway.

Plain-English Research Summary

This study explored how AOD9604 affects fat-cell biology in laboratory and mouse models. The researchers examined whether the peptide changed β3-adrenergic receptor expression and pathways associated with lipid storage and mobilization. Because the work was conducted in cells and animals, it does not establish a human treatment effect or clinical safety profile.

Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health

Authors: Margret I. Moré and David Kenley

Publication: Journal of Endocrinology and Metabolism, 2014;4(3):64–77

DOI: 10.14740/jem213w

Reference: View publication

This publication reported a series of non-clinical investigations involving AOD9604, including an Ames bacterial reverse-mutation test, an in-vitro chromosome-aberration assay using Chinese hamster ovary cells, a rat bone-marrow micronucleus study, chronic toxicology studies, and pharmacokinetic research in animal models.

In the reported Ames test, AOD9604 did not produce a biologically significant increase in revertant colonies. The chromosome-aberration assessment did not identify a consistent clastogenic response, although high concentrations were associated with precipitation and some cell-cycle effects. The animal toxicology studies described in the publication reported no clear treatment-related genotoxicity signal under the tested conditions.

The publication also reported rapid degradation of AOD9604 in biological matrices. In rat plasma at room temperature, the reported serum half-life was approximately four minutes, with sequential amino-terminal peptide fragments identified by mass spectrometry.

Plain-English Research Summary

This publication examined several laboratory safety and metabolism endpoints rather than clinical use. It reported no consistent evidence of mutagenic or chromosome-damaging activity under the test conditions. The study also found that AOD9604 is rapidly broken down in biological samples, producing identifiable peptide fragments.

Detection and In Vitro Metabolism of AOD9604

Authors: Holly D. Cox, Stacy J. Smeal, Cole M. Hughes, James E. Cox, and Daniel Eichner

Publication: Drug Testing and Analysis, 2015;7(1):31–38

DOI: 10.1002/dta.1715

Reference: View publication

This study investigated the in-vitro metabolism of AOD9604 in human serum and rat plasma. Using liquid chromatography–mass spectrometry, the researchers examined the peptide’s degradation kinetics and identified cleavage products generated by endogenous proteases.

The study also developed analytical methods for detecting AOD9604 and its metabolites in biological samples. These methods provide a framework for laboratory identification, metabolism research, and analytical testing of peptide fragments.

Plain-English Research Summary

This study examined how AOD9604 breaks down in biological samples and which peptide fragments are produced. The findings support the use of LC-MS-based methods to identify AOD9604 and its metabolites during laboratory analysis. The results describe in-vitro metabolism and analytical detection, not human dosing, therapeutic use, or clinical effectiveness.

Standard Research Disclaimer

Research Use Only. Not for use in diagnostic tests.

This product is solely intended for research purposes as a chemical compound. It is designated exclusively for in-vitro testing and laboratory experimentation. All information provided about this product is educational and should be evaluated by appropriately qualified research personnel.

By law, bodily introduction of this product into humans or animals is strictly prohibited. This compound must not be used, administered, or represented as a drug, food, dietary supplement, cosmetic, diagnostic material, or medical treatment. It is not intended to diagnose, treat, cure, or prevent any disease. It should be handled only by licensed and qualified professionals in an appropriately equipped laboratory and in accordance with applicable laws, institutional procedures, and relevant safety requirements.